Overview

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2019-08-23

Target enrollment:

Participant gender:

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.

Phase:

Phase 2

Details

Lead Sponsor:

Nicox Ophthalmics, Inc.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions